X

Trial Profile

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Radium 223 chloride (Primary)
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms COMRADE

Most Recent Events

01 Aug 2024 Status changed from suspended to active, no longer recruiting.
18 Jan 2024 Status changed from recruiting to suspended for the evaluation of enrolled patients.
02 Dec 2023 Planned End Date changed from 30 Nov 2023 to 30 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com